INTRODUCTION
The Burkholderia cepacia complex (Bcc) is a group of Gram-negative bacteria that can cause serious respiratory infections in immunocompromised individuals. Patients with cystic fibrosis (CF) are particularly at risk, where Bcc infections are associated with a worse prognosis and early death (LiPuma, 2010; Peeters et al., 2013) . The large majority of CF patients infected with Bcc develop a chronic infection that can last for years, leading to progressive loss of lung function. Also, a number of Bcc-infected patients may develop a rapid and fatal necrotizing pneumonia known as 'cepacia syndrome' . Most of the 20 described Bcc species have been isolated from CF pulmonary infections, but there is a disproportionate distribution of Bcc species, and the prevalence described for each species may vary depending on the country and CF centre under consideration Govan et al., 2007; Drevinek & Mahenthiralingam, 2010) . Nevertheless, Burkholderia cenocepacia and Burkholderia multivorans account for most (80 %) of the Bcc infections in CF patients worldwide (Drevinek and Mahenthiralingam, 2010; LiPuma, 2010; Peeters et al., 2013) , with B. cenocepacia being considered the most serious Bcc pathogen in CF Drevinek & Mahenthiralingam, 2010) . Consequently, most of the research dedicated to Bcc pathogenicity in CF has been focused on this species, and information regarding the impact of other Bcc species on clinical outcome is still scarce. However, epidemiological studies have shown that other Bcc species are also associated with poor prognosis, patient-to-patient transmission, chronic or transient infections, and cepacia syndrome (Biddick et al., 2003; Cunha et al., 2003 Cunha et al., , 2007 Kalish et al., 2006; Drevinek & Mahenthiralingam, 2010; LiPuma, 2010; Moreira et al., 2014) .
In the last few years, the taxonomy of the Bcc has evolved significantly, with the description of novel species (Yabuuchi et al., 2000; Coenye et al., 2001; Vandamme et al., 2002; Vermis et al., 2002 Vermis et al., , 2004 LiPuma, 2005; Vanlaere et al., 2008 Vanlaere et al., , 2009 Peeters et al., 2013; Smet et al., 2015) . Multicenter studies conducted up to 2009 revealed the existence of several clusters of isolates that do not group with the Bcc species described at the time. One divergent group was classified as belonging to Bcc recA RFLP type K (Vermis et al., 2002; Baldwin et al., 2005; Dalmastri et al., 2005 Dalmastri et al., , 2007 Payne et al., 2005; Mahenthiralingam et al., 2006) . After that date, Vanlaere and co-workers re-examined the taxonomic position and structure of taxon K (also known as group K), and proposed two novel species, Burkholderia contaminans and Burkholderia lata (Vanlaere et al., 2009) . The group of previously unclassified Bcc isolates of taxon K (Vermis et al., 2002; Baldwin et al., 2005; Dalmastri et al., 2005 Dalmastri et al., , 2007 Payne et al., 2005; Mahenthiralingam et al., 2006) includes bacteria isolated worldwide from human and environmental sources, namely from sputum cultures of CF patients in the UK, Italy, Portugal, USA, Canada, China, Brazil, Argentina and Australia (Cunha et al., 2003 (Cunha et al., , 2007 Campana et al., 2005; Assaad et al., 2006; Mahenthiralingam et al., 2006; Jordá-Vargas et al., 2008; Fang et al., 2010; Martina et al., 2013; Ramsay et al., 2013) , as well as from river water, human-built water reservoirs, soil, roots, animals, pharmaceutical products, such as contaminated nasal spray, personal care products and domestic products (Souza et al., 2004; Mahenthiralingam et al., 2006 Mahenthiralingam et al., , 2008 Martin et al., 2011) . B. contaminans has a low prevalence in CF patients worldwide, with remarkable exceptions in Argentina and in Spain (Martina et al., 2013) . Several reports of B. contaminans outbreaks amongst non-CF patients in Argentina and Brazil have also been also published, suggesting the existence of regional spreading of B. contaminans and other Bcc species between bordering countries (Mahenthiralingam et al., 2000; Agodi et al., 2002; Magalhães et al., 2003; Shehabi et al., 2004; Souza et al., 2004; Woods et al., 2004) . In the present work we have re-examined the taxonomic position, at the species level, of several isolates from our Bcc collection, recovered from CF patients receiving care at the major Portuguese CF Treatment Center, at Hospital de Santa Maria (HSM), in Lisbon. These isolates were obtained over 15 years of epidemiological surveillance of respiratory infections involving Bcc, and the study is focused on isolates previously classified as Bcc recA RFLP type K. This study also extends to isolates more recently obtained from a chronically infected patient known to harbour Bcc recA RFLP type K isolates, and provides insights into the potential clinical impact of a species that is rarely associated with CF infections.
METHODS
Bacterial isolates and culture conditions. The Bcc isolates used in this work (Table 1) were obtained from the HSM CF Center, Lisbon, Portugal, over the period of 1995 to 2010, from CF patients' respiratory secretions. According to the hospital's routine, sputum samples are obtained from CF patients every 2-3 months, during periodic consultations to monitor their clinical status, or more often for patients showing clinical deterioration. The seven patients indicated in Table 1 were found to be infected with Bcc recA RFLP type K, and the isolates were gathered from the date of their detection until the date of eradication or until patient death. Some of these isolates were previously classified as B. cepacia (Cunha et al., 2003 (Cunha et al., , 2007 , while others were examined molecularly for the first time in the present work and were obtained from a CF patient who continued to be chronically colonized with Bcc RFLP profile K after the date of previously published studies. Bacterial cultures are stored at 280 uC in 1:1 (v/v) glycerol. When in use, bacteria were cultivated on Pseudomonas isolation agar (PIA; Difco) plates or on Luria-Bertani agar (LB agar; Difco) plates.
Species identification and genotyping. Total genomic DNA from each isolate, previously cultured overnight in LB medium with orbital agitation at 37 uC, was extracted using a cell and tissue kit (Gentra Systems; Qiagen). The concentration of genomic DNA solutions was estimated using an ND-1000 spectrophotometer (NanoDrop).
The recA PCR RFLP analysis was performed by amplification of the entire recA gene (1040 bp) using specific primers for bacteria belonging to the Bcc (BCR1 59-TGACCGCCGAGAAGAGCAA-39; BCR2 59-CTCTTCTTCGTCCATCGCCTC-39), as previously described by Mahenthiralingam et al. (2000) . Bcc recA amplicons were digested with Hae III (Amersham Biosciences) restriction endonuclease, and the restriction fragments were separated by electrophoresis in 2 % (w/v) agarose gels. The RFLP patterns obtained for the Bcc isolates examined were compared with those reported in the literature (Mahenthiralingam et al., 2000; Vermis et al., 2002; Leite et al., 2011) .
The identification of the clinical isolates at the species level was performed using two different methods: multilocus sequence typing (MLST) analysis and hisA gene sequence analysis. MLST analysis was performed as previously described (Coutinho et al., 2011) . Amplification was carried out using a Gene Amp PCR System 2700 (Applied Biosystems). The amplification products were confirmed following separation of PCR products by 0.9 % (w/v) horizontal agarose gel electrophoresis, and the bands were excised, purified using a gel extraction kit (JETquick spin column technique; Genomed) and sequenced. The sequence data for each isolate was compared with known sequences from the Bcc MLST database (http://pubmlst.org/ bcc), using BioEdit software (www.mbio.ncsu.edu/bioedit/bioedit.html). The alleles for each of the seven loci were assigned and the allelic profile (string of seven integers) was used to define the sequence type (ST), using the same database. The allelic profile of the isolates under study was submitted and added to the Bcc MLST database. The hisA gene sequence analysis was performed by PCR amplification of the hisA gene region (89 to 530 bp) of 442 bp as previously described by Papaleo et al. (2010) . Briefly, in a 50 ml reaction mixture containing 50 ng of DNA template, 2 U Taq DNA polymerase (Biotaq Taq polymerase; Bioline), 250 mM each dNTP, 0.6 mM each primer (forward -AGGACCCGGCGGCGAT; reverse -TGCAGCATCCC-GTCGCG), 1.5 mM MgCl 2 and 1|PCR buffer (10|; supplied by the polymerase manufacturer) were added. The amplification reaction was carried out using an initial step of denaturation for 2 min at 95 uC, followed by 30 cycles of 30 s at 95 uC for denaturation, 45 s at 67 uC for primer annealing, and 1 min at 72 uC for polymerization, followed by a final extension step of 72 uC for 10 min, using a GeneAmp PCR System 2700 (Applied Biosystems). Amplification was confirmed by electrophoresis in 0.9 % (w/v) agarose gels. The PCR products were purified using the PCR product purification spin kit (JETquick spin column technique; Genomed), according to the manufacturer's instructions, and sequenced. The sequences were compared with the eleven-letter code for the Bcc hisA gene, which allows species identification as detailed by Papaleo et al. (2010) . Ethics. Studies involving clinical Bcc isolates obtained as part of the hospital routine were approved by the hospital ethics committee and the patients' anonymity is preserved. Consent was obtained from the patients' legal guardian for the use of these isolates in research.
RESULTS AND DISCUSSION
Identification and molecular typing of B. contaminans clinical isolates
The 56 Bcc isolates examined in this study were obtained from seven paediatric CF patients from 1995 to 2010. They include those formerly classified as B. cepacia recA profile K and those more recently isolated from one chronically infected patient found to be infected with profile K isolates in previously published epidemiological surveys (Cunha et al., 2003 (Cunha et al., , 2007 . The profile K was confirmed for all the isolates based on recA gene amplification and restriction with Hae III of the amplified products followed by RFLP analysis. However, since recA sequencebased identification of the so-called taxon K bacteria is considered problematic and can only solve part of the species complexity in this lineage (Vanlaere et al., 2009 ), a number of isolates, retrieved from chronically infected patients at different colonization times, were examined by MLST analysis by assessing seven housekeeping genes (atpD, gltB, gyrB, recA, lepA, phaC and trpB) (Baldwin et al., 2005) . All the taxon K isolates examined were considered to be isogenic given their identical allelic profile [all of them gave rise to the same sequence type (ST-96)] (Table 1) . Since MLST analysis is a costly and time-consuming procedure, it was limited to the analysis of a small number of isolates. Therefore, our option was to characterize molecularly the remaining isolates using hisA gene sequence analysis, since this method has also been validated for Bcc species determination (Papaleo et al., 2010) . Altogether, the molecular analyses performed revealed that the isolates previously classified as belonging to B. cepacia recA profile K, as well as the isolates more recently retrieved from one patient that had been infected with recA profile K isolates from 2004 to 2006 and continued to be infected with the same taxon K bacteria until 2010, are B. contaminans. Moreover, this was the only species of taxon K found among the Bcc isolates examined during the surveillance period.
Clinical impact of B. contaminans infections in CF
Two of the paediatric patients with Bcc (G and AF) were considered chronically infected with B. contaminans, i.e. with 50 % or more of positive Bcc cultures within a 12-month period (Lee et al., 2003) . Both patients died, one with cepacia syndrome (patient G) and the other following long-term infection (6 years) and clinical deterioration (patient AF). However, patient AF was also found to be co-infected with B. cenocepacia IIIA and IIIB and with bacteria from other genera (Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae). Patient G was co-infected with P. aeruginosa and with Bcc bacteria for 8 months and, during this time, three Bcc isolates were obtained during periodic visits to monitor the patient's clinical status: a B. cenocepacia IIIB isolate was collected first, followed by a B. contaminans isolate, and the last isolate, obtained before the patient's death with cepacia syndrome, belonged to B. cenocepacia IIIB (Table 2 ). Since patient G was co-infected with B. cenocepacia, his death with cepacia syndrome cannot simply be attributed to B. contaminans, especially since the last isolate retrieved close to the patient's death was classified as B. cenocepacia IIIB. Patient AF was infected with Bcc for almost 6 years but most of the isolates retrieved (29) belonged to the B. contaminans species. However, isolates belonging to B. cepacia (2), Burkholderia dolosa (1), B. cenocepacia IIIB (1) and B. cenocepacia IIIA species (8) were also obtained (Table 2) .
Remarkably, although transient co-infection with B. cenocepacia IIIA and IIIB occurred in patient AF, B. contaminans prevailed until the patient's death as recently reported for B. dolosa (Moreira et al., 2014) , contrasting with the generalized idea that B. cenocepacia bacteria replace other Bcc species present in the lungs (Bernhardt et al., 2003) . The registered co-colonization of the patients with B. cenocepacia and other non-Burkholderia bacteria raises the question whether B. contaminans was the main cause of death. However, in the case of patient AF, during the last year of life, only B. contaminans isolates were retrieved suggesting that B. contaminans contributed to the clinical outcome deterioration of the infected patient (Tables 1 and 2 §Sa, S. aureus; Hi, H. influenzae; Pa, P. aeruginosa. Burkholderia contaminans at a cystic fibrosis centre year following isolation) and the FEV1 values, which reached 60 % 1 year before the isolation of the first B. contaminans bacterium, decreased to 44 % during the first year following isolation of Bcc bacteria that consisted mostly of B. contaminans. In summary, the inexorable decline in the FEV1 value appears to have been related to B. contaminans infection, although it is impossible to be sure about the clinical impact of this species in a coinfected patient.
The other five patients (A, E, F, W and X) infected with B. contaminans cannot be considered as chronically infected. Patients A, E and F were infected with Bcc bacteria for less than 1 month. Two isolates belonging to B. contaminans and B. cenocepacia IIIB were isolated from patient A, but spontaneous clearance occurred. For the other two patients, only one isolate of B. contaminans was apparently retrieved because, following the initial B. contaminans isolation, the patients died. Both patients were also coinfected with P. aeruginosa (patient E) or S. aureus, H. influenzae and P. aeruginosa (patient F). Patients W and X, who were also co-infected with S. aureus, H. influenzae and P. aeruginosa, were able to spontaneously eradicate B. contaminans after 5 or 3 months of the first isolation, respectively. In summary, the species B. contaminans was associated either with chronic infection in CF patients (the case of patients G and AF), or with a transient infection that, in certain cases, led to spontaneous clearance (the case of patients A, W and X).
The cepacian-producing strain IST408 belongs to B. contaminans and not to B. cepacia
Among the isolates whose taxonomic position was reexamined at the species level in the present work is IST408, an isolate that was previously classified as B. cepacia Cunha et al., 2003 Cunha et al., , 2004 Moreira et al., 2003; Ferreira et al., 2011) . B. contaminans IST408 has been the focus of our studies regarding exopolysaccharide (EPS) biosynthesis in Bcc (Cescutti et al., 2000; Richau et al., 2000; Sist et al., 2003; Ferreira et al., 2011) , since it was consistently the highest-producing strain tested among the clinical isolates available, at that time, in our culture collection. The designation of the EPS, which was chemically and structurally characterized, as 'cepacian', was based on the idea that the producing isolate belonged to the species B. cepacia (Cescutti et al., 2000; Richau et al., 2000; Sist et al., 2003) . Remarkably, all of the previously characterized B. contaminans isolates (formerly considered B. cepacia) were found to be, in general, high EPS producers, compared with isolates from the other species examined (B. cenocepacia, B. cepacia, B. multivorans and Burkholderia stabilis) (Cunha et al., 2004) ). Although the number of Bcc isolates tested concerning the level of EPS production was small and includes a large number of isogenic variants, this observation concerning the high EPSproducing capacity of B. contaminans isolates certainly deserves attention in future studies.
B. contaminans infections in the Portuguese CF population examined
Based on the epidemiological survey carried out for the past two decades in the HSM CF Treatment Center, we found B. contaminans isolates in 17 % of the CF population infected with Bcc (i.e. in seven patients -three girls and four boys -of a total of 41 patients). The prevalence of B. contaminans in CF patients worldwide is low, with remarkable exceptions registered in Argentina (Martina et al., 2013) and Spain (Medina-Pascual et al., 2015) , presumably resulting from patient to patient transmission or other sources of infection, such as environmental or pharmaceutical products.
Some of the isolates that were reclassified as B. contaminans in this study had been previously classified as B. cepacia. Remarkably, the CF population under surveillance at the CF Treatment Center of HSM is well known for having an exceptionally high representation of B. cepacia ( Fig. 1 ) (Cunha et al., 2007) . This abnormal prevalence was associated with an outbreak in 2003-2005 presumably caused by contaminated non-sterile saline solutions for nasal application, detected with our help during routine market surveillance by the Portuguese Medicines and Health Products Authority (INFARMED). B. cepacia strains with ribopatterns 17, 18, 19 and 20 were identified in several batches of the saline solutions examined and in infected CF patients. Notably, the isolates that are now reclassified as B. contaminans and that were retrieved during this critical period have ribopatterns 2 and 5 (Cunha et al., 2007) . Therefore, a direct causal link between the contaminated saline solutions and B. contaminans infections cannot be established at this time. Nevertheless, this hypothesis can neither be excluded. Indeed, several B. contaminans isolates were collected from patients during the period of maximal contamination with B. cepacia, which coincided with the identification of the contaminated saline solutions, and even if ribopatterns 2 and 5 were not detected in those solutions, the coincidence in time raises the possibility of a common source of infection. Also, a B. cepacia isolate 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 9 1 9 9 8 2 0 0 0 with ribopattern 17 was collected from patient AF (IST4221), who was found to be simultaneously infected with B. contaminans since 2004 (Table 1) .
CONCLUSIONS
This work describes the identification of 41 B. contaminans isolates retrieved from seven paediatric CF patients, two of them chronically infected over the course of 15 years of epidemiological surveillance of Bcc respiratory infections at the major Portuguese CF centre. The same CF population examined had been previously reported as having an exceptionally high representation of B. cepacia isolates (Cunha et al., 2007) . This fact was considered to be at least partially associated with a contamination of saline solutions for nasal application. However, 20 of those B. cepacia isolates, formerly classified as recA RFLP type K, were reclassified in this work as B. contaminans. Twenty-one additional B. contaminans isolates were obtained later from a chronically infected patient. This study reinforces the observation that this Portuguese CF population is infected with an abnormally high percentage of Bcc species that are rarely found in CF respiratory infections, namely B. cepacia and B. contaminans, and provides insight into the potential clinical impact of B. contaminans species. Isolates belonging to this species were retrieved from chronic and transient respiratory infections and were associated with lung function deterioration and the patient deceased from cepacia syndrome. However, since these patients were co-infected with B. cenocepacia and other non-Burkholderia bacteria, the role played by B. contaminans is unclear. During co-infection of at least one chronically infected patient, B. contaminans isolates were found to prevail over B. cenocepacia isolates.
